With many efforts to reduce recurrence and improve survival in early-stage NSCLC, a new generation of EGFR-TKIs has opened up a new era of adjuvant therapies after definitive surgery in recent years. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.